Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
| Name | Price | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IgG IgA IgM | Login | IgG IgA IgM | ||||||||||||||||
|
||||||||||||||||||
| CD156b | Login | CD156b | ||||||||||||||||
|
||||||||||||||||||
| NEUROFILAMENT | Login | NEUROFILAMENT | ||||||||||||||||
|
||||||||||||||||||
| IgG IgA IgM | Login | IgG IgA IgM | ||||||||||||||||
|
||||||||||||||||||
| XERODERMA PIGMENTOSUM PROTEIN GROUP G | Login | XERODERMA PIGMENTOSUM PROTEIN GROUP G | ||||||||||||||||
|
||||||||||||||||||
| Fluorogenic P300 (KAT3B) Assay Kit | Login | Fluorogenic P300 (KAT3B) Assay Kit | ||||||||||||||||
|
||||||||||||||||||
| Lysyl Oxidase-like 2 (LOXL2) Human Recombinant Protein (293) | Login | Lysyl Oxidase-like 2 (LOXL2) Human Recombinant Protein (293) | ||||||||||||||||
|
||||||||||||||||||
| Interleukin-6 Receptor | Login | Interleukin-6 Receptor | ||||||||||||||||
|
||||||||||||||||||
| Gastrin Releasing Peptide Human | Login | Gastrin Releasing Peptide Human | ||||||||||||||||
|
||||||||||||||||||
| Rat CD45 Antibody (Biotin) | Login | Rat CD45 Antibody (Biotin) | ||||||||||||||||
|
||||||||||||||||||
| Mouse CD16/CD32 Antibody (Biotin) | Login | Mouse CD16/CD32 Antibody (Biotin) | ||||||||||||||||
|
||||||||||||||||||
| Rat CD45 Antibody (FITC) | Login | Rat CD45 Antibody (FITC) | ||||||||||||||||
|
||||||||||||||||||
| Rat MHC Class II Antibody (Rt1D) | Login | Rat MHC Class II Antibody (Rt1D) | ||||||||||||||||
|
||||||||||||||||||
| Rat CD45.1 Antibody (FITC) | Login | Rat CD45.1 Antibody (FITC) | ||||||||||||||||
|
||||||||||||||||||
| Rat CD45 Antibody | Login | Rat CD45 Antibody | ||||||||||||||||
|
||||||||||||||||||
| Rat CD25 Antibody | Login | Rat CD25 Antibody | ||||||||||||||||
|
||||||||||||||||||
| Rat MHC Class II Antibody (RT1B) (FITC) | Login | Rat MHC Class II Antibody (RT1B) (FITC) | ||||||||||||||||
|
||||||||||||||||||
| Rat CD25 Antibody (Biotin) | Login | Rat CD25 Antibody (Biotin) | ||||||||||||||||
|
||||||||||||||||||
| Chlamydia Trachomatis IgA ELISA | Login | Chlamydia Trachomatis IgA ELISA | ||||||||||||||||
|
||||||||||||||||||
| Epstein-Barr Virus / VCA IgA ELISA | Login | Epstein-Barr Virus / VCA IgA ELISA | ||||||||||||||||
|
||||||||||||||||||
| Helicobacter Pylori (H. Pylori) IgA ELISA | Login | Helicobacter Pylori (H. Pylori) IgA ELISA | ||||||||||||||||
|
||||||||||||||||||
| Amylase, (Kinetic), 10 x 6ml | Login | Amylase, (Kinetic), 10 x 6ml | ||||||||||||||||
|
||||||||||||||||||
| Rat IgA Antibody (HRP) | Login | Rat IgA Antibody (HRP) | ||||||||||||||||
|
||||||||||||||||||
| Rat CD8 alpha Antibody (Biotin) | Login | Rat CD8 alpha Antibody (Biotin) | ||||||||||||||||
|
||||||||||||||||||
| Rat CD25 Antibody (FITC) | Login | Rat CD25 Antibody (FITC) | ||||||||||||||||
|
||||||||||||||||||


